U.S. President Joe Biden speaks about his administration's response to the Omicron variant at the National Institutes of Health (NIH) in Bethesda, Maryland on December 2, 2021. (Photo: Mandel Ngan/AFP via Getty Images)
US Praised for Plan to Transfer Covid Tech to WHO
"This is a turn toward sharing not only doses, but knowledge, which is the difference between charity and justice," said one public health advocate.
Public health advocates welcomed the Biden administration's announcement Thursday that the U.S. will share certain medical technologies used to produce Covid-19 tests, treatments, and vaccines with the World Health Organization as part of an effort to combat the global pandemic that continues to kill thousands of people each week.
"The immediate medical value of Thursday's announcement will depend on which NIH technologies are licensed."
The U.S. Department of Health and Human Services (HHS) said Thursday that it will offer unspecified technologies being developed by the National Institutes of Health (NIH) to the WHO's Covid-19 Technology Access Pool (C-TAP) for licensing through the United Nations-backed Medicines Patent Pool (MPP), which experts say will empower generic manufacturers to boost the global supply of lifesaving diagnostics, drugs, and jabs.
After being urged to share coronavirus-related knowledge for nearly two years by justice campaigners around the globe, "HHS is stepping up to share medical technology with the world," Peter Maybarduk, director of Public Citizen's Access to Medicines program, said in a statement.
"Early in the pandemic, WHO and many developing countries put forward C-TAP as a vehicle for sharing medical technology, so that researchers and manufacturers could help make available to people everywhere tests, treatment, and vaccine technology, and ultimately, improve on those medical tools," said Maybarduk. "The world's people have traveled a brutally hard path since, characterized by extreme shortages and a global vaccine apartheid that has contributed to countless deaths."
To date, just 13% of people in low-income countries have received at least one Covid-19 vaccine shot, according to Our World in Data. On the African continent, nearly 82% of people have yet to receive a single dose. Researchers at Public Citizen have warned that Pfizer is poised to replicate this inequity by imposing intellectual property restrictions on its Paxlovid treatment.
With Thursday's announcement, said Maybarduk, HHS is taking steps "to help catalyze WHO's vision of a more equitable future by offering publicly owned technologies from NIH, the world's premier biomedical research institution."
Thanking NIH for "its offer of innovative therapeutics, vaccines, and diagnostic methods for Covid-19," WHO Director General Tedros Adhanom Ghebreyesus said in a statement that the "voluntary sharing of technologies through nonexclusive agreements will not only help us put the pandemic behind us; it will also empower low- and middle-income countries to produce their own medical products and achieve equitable access."
However, Maybarduk stressed that "the immediate medical value of Thursday's announcement will depend on which NIH technologies are licensed."
The Washington Post reported that senior NIH official Anthony Fauci "declined to detail which technologies would be made available for licensing by other countries, saying the plan's details were 'still being ironed out.'"
According to the newspaper:
The new policy is not intended to apply to the vaccines and therapeutics that have been developed by private companies and are currently in the U.S. market, according to three people familiar with the plan who spoke on the condition of anonymity because they were not authorized to speak with the news media.
The United States is not expected to share NIH-developed technology that was used by Moderna, the vaccine maker that worked closely with the U.S. government in its messenger RNA vaccine. Foreign countries and developers have long petitioned for access to Moderna's technology and know-how, saying that it would allow them to more quickly replicate their own versions of Moderna's vaccine.
As Maybarduk explained, "NIH and NIH-supported research have been critical to the development of leading medical advances including the world's most effective Covid vaccine, NIH-Moderna." However, he pointed out, "many NIH-owned technologies are early stage or comprise only part of a final medical product."
"Thursday's announcement is not a substitute for fully funding the global Covid response."
"To facilitate new production of today's vaccines," Maybarduk said, it would be necessary for HHS "to require pharmaceutical firms to license technology"--something the agency has not yet indicated it plans to do.
"Thursday's announcement is not a substitute for fully funding the global Covid response," Maybarduk emphasized. Referring to President Joe Biden's newly unveiled pandemic plan, he said that "we are heartened to see the White House finally has asked Congress to further fund the global fight... but dismayed that the $5 billion requested falls short of the minimum $17 billion needed."
Maybarduk called the move by HHS "a turn toward sharing not only doses, but knowledge, which is the difference between charity and justice."
"It is a trajectory which if pursued with seriousness of purpose can improve resilience to future pandemics and bring a measure of justice to a terribly unjust time," he said.
Noting that "the U.S. government is developing a pan-coronavirus vaccine, with hopes that it will prove effective against multiple variants," Maybarduk added that "Thursday's announcement forges a path for sharing this publicly owned technology with humanity, as well."
FINAL DAY! This is urgent.
Dear Common Dreams reader, It’s been nearly 30 years since I co-founded Common Dreams with my late wife, Lina Newhouser. We had the radical notion that journalism should serve the public good, not corporate profits. It was clear to us from the outset what it would take to build such a project. No paid advertisements. No corporate sponsors. No millionaire publisher telling us what to think or do. Many people said we wouldn't last a year, but we proved those doubters wrong. Together with a tremendous team of journalists and dedicated staff, we built an independent media outlet free from the constraints of profits and corporate control. Our mission from the outset was simple. To inform. To inspire. To ignite change for the common good. Building Common Dreams was not easy. Our survival was never guaranteed. When you take on the most powerful forces—Wall Street greed, fossil fuel industry destruction, Big Tech lobbyists, and uber-rich oligarchs who have spent billions upon billions rigging the economy and democracy in their favor—the only bulwark you have is supporters who believe in your work. But here’s the urgent message from me today. It’s never been this bad out there. And it’s never been this hard to keep us going. At the very moment Common Dreams is most needed and doing some of its best and most important work, the threats we face are intensifying. Right now, with just hours left in our Spring Campaign, we're still falling short of our make-or-break goal. When everyone does the little they can afford, we are strong. But if that support retreats or dries up, so do we. Can you make a gift right now to make sure Common Dreams not only survives but thrives? There is no backup plan or rainy day fund. There is only you. —Craig Brown, Co-founder |
Public health advocates welcomed the Biden administration's announcement Thursday that the U.S. will share certain medical technologies used to produce Covid-19 tests, treatments, and vaccines with the World Health Organization as part of an effort to combat the global pandemic that continues to kill thousands of people each week.
"The immediate medical value of Thursday's announcement will depend on which NIH technologies are licensed."
The U.S. Department of Health and Human Services (HHS) said Thursday that it will offer unspecified technologies being developed by the National Institutes of Health (NIH) to the WHO's Covid-19 Technology Access Pool (C-TAP) for licensing through the United Nations-backed Medicines Patent Pool (MPP), which experts say will empower generic manufacturers to boost the global supply of lifesaving diagnostics, drugs, and jabs.
After being urged to share coronavirus-related knowledge for nearly two years by justice campaigners around the globe, "HHS is stepping up to share medical technology with the world," Peter Maybarduk, director of Public Citizen's Access to Medicines program, said in a statement.
"Early in the pandemic, WHO and many developing countries put forward C-TAP as a vehicle for sharing medical technology, so that researchers and manufacturers could help make available to people everywhere tests, treatment, and vaccine technology, and ultimately, improve on those medical tools," said Maybarduk. "The world's people have traveled a brutally hard path since, characterized by extreme shortages and a global vaccine apartheid that has contributed to countless deaths."
To date, just 13% of people in low-income countries have received at least one Covid-19 vaccine shot, according to Our World in Data. On the African continent, nearly 82% of people have yet to receive a single dose. Researchers at Public Citizen have warned that Pfizer is poised to replicate this inequity by imposing intellectual property restrictions on its Paxlovid treatment.
With Thursday's announcement, said Maybarduk, HHS is taking steps "to help catalyze WHO's vision of a more equitable future by offering publicly owned technologies from NIH, the world's premier biomedical research institution."
Thanking NIH for "its offer of innovative therapeutics, vaccines, and diagnostic methods for Covid-19," WHO Director General Tedros Adhanom Ghebreyesus said in a statement that the "voluntary sharing of technologies through nonexclusive agreements will not only help us put the pandemic behind us; it will also empower low- and middle-income countries to produce their own medical products and achieve equitable access."
However, Maybarduk stressed that "the immediate medical value of Thursday's announcement will depend on which NIH technologies are licensed."
The Washington Post reported that senior NIH official Anthony Fauci "declined to detail which technologies would be made available for licensing by other countries, saying the plan's details were 'still being ironed out.'"
According to the newspaper:
The new policy is not intended to apply to the vaccines and therapeutics that have been developed by private companies and are currently in the U.S. market, according to three people familiar with the plan who spoke on the condition of anonymity because they were not authorized to speak with the news media.
The United States is not expected to share NIH-developed technology that was used by Moderna, the vaccine maker that worked closely with the U.S. government in its messenger RNA vaccine. Foreign countries and developers have long petitioned for access to Moderna's technology and know-how, saying that it would allow them to more quickly replicate their own versions of Moderna's vaccine.
As Maybarduk explained, "NIH and NIH-supported research have been critical to the development of leading medical advances including the world's most effective Covid vaccine, NIH-Moderna." However, he pointed out, "many NIH-owned technologies are early stage or comprise only part of a final medical product."
"Thursday's announcement is not a substitute for fully funding the global Covid response."
"To facilitate new production of today's vaccines," Maybarduk said, it would be necessary for HHS "to require pharmaceutical firms to license technology"--something the agency has not yet indicated it plans to do.
"Thursday's announcement is not a substitute for fully funding the global Covid response," Maybarduk emphasized. Referring to President Joe Biden's newly unveiled pandemic plan, he said that "we are heartened to see the White House finally has asked Congress to further fund the global fight... but dismayed that the $5 billion requested falls short of the minimum $17 billion needed."
Maybarduk called the move by HHS "a turn toward sharing not only doses, but knowledge, which is the difference between charity and justice."
"It is a trajectory which if pursued with seriousness of purpose can improve resilience to future pandemics and bring a measure of justice to a terribly unjust time," he said.
Noting that "the U.S. government is developing a pan-coronavirus vaccine, with hopes that it will prove effective against multiple variants," Maybarduk added that "Thursday's announcement forges a path for sharing this publicly owned technology with humanity, as well."
Public health advocates welcomed the Biden administration's announcement Thursday that the U.S. will share certain medical technologies used to produce Covid-19 tests, treatments, and vaccines with the World Health Organization as part of an effort to combat the global pandemic that continues to kill thousands of people each week.
"The immediate medical value of Thursday's announcement will depend on which NIH technologies are licensed."
The U.S. Department of Health and Human Services (HHS) said Thursday that it will offer unspecified technologies being developed by the National Institutes of Health (NIH) to the WHO's Covid-19 Technology Access Pool (C-TAP) for licensing through the United Nations-backed Medicines Patent Pool (MPP), which experts say will empower generic manufacturers to boost the global supply of lifesaving diagnostics, drugs, and jabs.
After being urged to share coronavirus-related knowledge for nearly two years by justice campaigners around the globe, "HHS is stepping up to share medical technology with the world," Peter Maybarduk, director of Public Citizen's Access to Medicines program, said in a statement.
"Early in the pandemic, WHO and many developing countries put forward C-TAP as a vehicle for sharing medical technology, so that researchers and manufacturers could help make available to people everywhere tests, treatment, and vaccine technology, and ultimately, improve on those medical tools," said Maybarduk. "The world's people have traveled a brutally hard path since, characterized by extreme shortages and a global vaccine apartheid that has contributed to countless deaths."
To date, just 13% of people in low-income countries have received at least one Covid-19 vaccine shot, according to Our World in Data. On the African continent, nearly 82% of people have yet to receive a single dose. Researchers at Public Citizen have warned that Pfizer is poised to replicate this inequity by imposing intellectual property restrictions on its Paxlovid treatment.
With Thursday's announcement, said Maybarduk, HHS is taking steps "to help catalyze WHO's vision of a more equitable future by offering publicly owned technologies from NIH, the world's premier biomedical research institution."
Thanking NIH for "its offer of innovative therapeutics, vaccines, and diagnostic methods for Covid-19," WHO Director General Tedros Adhanom Ghebreyesus said in a statement that the "voluntary sharing of technologies through nonexclusive agreements will not only help us put the pandemic behind us; it will also empower low- and middle-income countries to produce their own medical products and achieve equitable access."
However, Maybarduk stressed that "the immediate medical value of Thursday's announcement will depend on which NIH technologies are licensed."
The Washington Post reported that senior NIH official Anthony Fauci "declined to detail which technologies would be made available for licensing by other countries, saying the plan's details were 'still being ironed out.'"
According to the newspaper:
The new policy is not intended to apply to the vaccines and therapeutics that have been developed by private companies and are currently in the U.S. market, according to three people familiar with the plan who spoke on the condition of anonymity because they were not authorized to speak with the news media.
The United States is not expected to share NIH-developed technology that was used by Moderna, the vaccine maker that worked closely with the U.S. government in its messenger RNA vaccine. Foreign countries and developers have long petitioned for access to Moderna's technology and know-how, saying that it would allow them to more quickly replicate their own versions of Moderna's vaccine.
As Maybarduk explained, "NIH and NIH-supported research have been critical to the development of leading medical advances including the world's most effective Covid vaccine, NIH-Moderna." However, he pointed out, "many NIH-owned technologies are early stage or comprise only part of a final medical product."
"Thursday's announcement is not a substitute for fully funding the global Covid response."
"To facilitate new production of today's vaccines," Maybarduk said, it would be necessary for HHS "to require pharmaceutical firms to license technology"--something the agency has not yet indicated it plans to do.
"Thursday's announcement is not a substitute for fully funding the global Covid response," Maybarduk emphasized. Referring to President Joe Biden's newly unveiled pandemic plan, he said that "we are heartened to see the White House finally has asked Congress to further fund the global fight... but dismayed that the $5 billion requested falls short of the minimum $17 billion needed."
Maybarduk called the move by HHS "a turn toward sharing not only doses, but knowledge, which is the difference between charity and justice."
"It is a trajectory which if pursued with seriousness of purpose can improve resilience to future pandemics and bring a measure of justice to a terribly unjust time," he said.
Noting that "the U.S. government is developing a pan-coronavirus vaccine, with hopes that it will prove effective against multiple variants," Maybarduk added that "Thursday's announcement forges a path for sharing this publicly owned technology with humanity, as well."